Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28878992 | 0.95 | POLB (0.50) | S1PR4S1PR1S1PR5POLBKMT2A | |
| SCHEMBL12348250 | 0.92 | S1PR4 (0.45) | S1PR4S1PR1S1PR5POLBTLR8 | |
| SCHEMBL26554639 | 0.89 | TLR8 (0.52) | S1PR4S1PR1S1PR5TLR8MAPT | |
| SCHEMBL8620324 | 0.85 | GAA (0.55) | NPC1RAB9AMAPT | |
| SCHEMBL11416418 | 0.83 | S1PR4 (0.48) | S1PR4S1PR1S1PR5TLR8 | |
| SCHEMBL28878987 | 0.83 | S1PR4 (0.61) | S1PR4S1PR1S1PR5KMT2AMAPT | |
| SCHEMBL10578214 | 0.82 | POLB (0.45) | POLBKMT2AMAPT | |
| SCHEMBL9305960 | 0.82 | S1PR4 (0.47) | S1PR4S1PR1S1PR5TLR8 | |
| SCHEMBL9305638 | 0.82 | S1PR4 (0.47) | S1PR4S1PR1S1PR5TLR8 | |
| SCHEMBL11223673 | 0.81 | TUBB4A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | S1PR4 3419/4885S1PR1 3244/4885S1PR5 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.